Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have signed a consent form agreeing to take part in the study
- People who have been diagnosed with triple-negative breast cancer (TNBC), confirmed through a tissue sample test
- People whose doctor has recommended chemotherapy combined with immunotherapy before surgery (called neoadjuvant treatment)
- People aged between 18 and 75 years old
- People who are covered by a social protection or health insurance scheme
Who may not be able to join:
- People who are pregnant or currently breastfeeding
- People who have a medical reason that prevents them from receiving immunotherapy
- People with a specific type of breast cancer that affects the skin and causes inflammation (known as inflammatory breast cancer, or T4d stage)
- People whose cancer has spread to other parts of the body (metastatic cancer)
- People who have a known allergy to iodine or gadolinium (substances used in certain medical scans)
- People who have breast implants (as these can interfere with certain imaging tests used in the study)
- People who experience severe anxiety in enclosed spaces (claustrophobia), as MRI scans are required
- People who have kidney-related reasons that prevent the safe use of contrast dyes used in scans, as assessed according to French radiology guidelines (confirm with trial site)
- People who have ferromagnetic metal in their body (metal that is affected by magnets, which can be unsafe in MRI scanners)
- People with poorly controlled diabetes, where blood sugar levels remain above a certain threshold
- People who are unable to understand or follow the requirements of the study for any reason, including language barriers, psychological difficulties, or geographical challenges
- People who are under legal guardianship or a court-ordered protection arrangement
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Florian Clatot, Md, PhD, Centre Henri Becquerel
Phone: +33276673004
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
concordance rate between quadrimodal radiological assessment (ultrasound, angiography/mammography, MRI, PET-CT) and histologically-obtained response following neoadjuvant chemo-immunotherapy in patients with triple-negative breast cancer (TNBC).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.